Charges lead to large first-quarter loss for Chiron
This article was originally published in Clinica
Due to a $349 million charge mainly related to its partnership with Ciba, Chiron recorded a net loss of $386 million compared with net income of $4.8 million in the first quarter a year earlier. Sales jumped to $218 million from $91 million because of increased product sales through newly-acquired diagnostics subsidiary Ciba Corning and Chiron's full ownership of vaccine manufacturer Biocine.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.